Contemporary paediatric clinical trials have improved 5-year event-free survival above 85%
and 5-year overall survival above 90% in B-cell acute lymphoblastic leukaemia (ALL) in …

The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …

Advances in genomic research and risk-directed therapy have led to improvements in the
long-term survival and quality of life outcomes of patients with childhood acute lymphoblastic …

Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class
rearrangements | Blood | American Society of Hematology Skip to Main Content Advertisement …

The need for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with
Philadelphia chromosome–negative (Ph−) acute lymphoblastic leukemia (ALL) with high …

Improvements in risk-directed treatment and supportive care, together with increased
reliance on both national and international collaborative studies, have made childhood …

Lymphoblastic lymphoma (LBL) is the second most common type of Non‐Hodgkin
Lymphoma (NHL) in childhood and adolescence, accounting for 25–35% of all cases. The …

Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) are
recognized as a unique population with specific characteristics and needs. In adolescents …

Outcomes of pediatric and young adult patients diagnosed with acute lymphoblastic
leukemia (ALL) have improved significantly in the past few decades. Treatment advances …

PURPOSE We determined the prognostic factors and utility of allogeneic hematopoietic cell
transplantation among children with newly diagnosed hypodiploid acute lymphoblastic …